BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25686657)

  • 1. Diffusion-weighted magnetic resonance imaging in preoperative assessment of non-small cell lung cancer.
    Nomori H; Cong Y; Abe M; Sugimura H; Kato Y
    J Thorac Cardiovasc Surg; 2015 Apr; 149(4):991-6. PubMed ID: 25686657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathologic node-negative clinical stage IA lung adenocarcinoma for optimal candidates undergoing sublobar resection.
    Tsutani Y; Miyata Y; Nakayama H; Okumura S; Adachi S; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1365-71. PubMed ID: 22883546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The maximum standardized 18F-fluorodeoxyglucose uptake on positron emission tomography predicts lymph node metastasis and invasiveness in clinical stage IA non-small cell lung cancer.
    Maeda R; Isowa N; Onuma H; Miura H; Harada T; Touge H; Tokuyasu H; Kawasaki Y
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):79-82. PubMed ID: 19366724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study.
    Higashi K; Ito K; Hiramatsu Y; Ishikawa T; Sakuma T; Matsunari I; Kuga G; Miura K; Higuchi T; Tonami H; Yamamoto I
    J Nucl Med; 2005 Feb; 46(2):267-73. PubMed ID: 15695786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.
    Li X; Zhang H; Xing L; Xu X; Xie P; Ma H; Zhang L; Chen M; Sun X; Xu W; Chen L; Yu J
    Clin Lung Cancer; 2013 Sep; 14(5):568-73. PubMed ID: 23835164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardized Uptake Values in the Primary Lesions of Non-Small-Cell Lung Cancer in FDG-PET/CT Can Predict Regional Lymph Node Metastases.
    Nakamura H; Saji H; Marushima H; Kimura H; Tagaya R; Kurimoto N; Hoshikawa M; Takagi M
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1388-93. PubMed ID: 25900205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of sublobar resection for c-stage IA non-small cell lung cancer based on a combination of structural imaging by CT and functional imaging by FDG PET.
    Yoshioka M; Ichiguchi O
    Ann Thorac Cardiovasc Surg; 2009 Apr; 15(2):82-8. PubMed ID: 19471220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
    Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factors.
    Usuda K; Funasaki A; Sekimura A; Motono N; Matoba M; Doai M; Yamada S; Ueda Y; Uramoto H
    Med Oncol; 2018 Apr; 35(5):66. PubMed ID: 29633024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?
    Ohba Y; Nomori H; Mori T; Ikeda K; Shibata H; Kobayashi H; Shiraishi S; Katahira K
    J Thorac Cardiovasc Surg; 2009 Aug; 138(2):439-45. PubMed ID: 19619793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.
    Nomori H; Cong Y; Sugimura H; Kato Y
    Surg Today; 2016 Oct; 46(10):1146-51. PubMed ID: 26658716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
    Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography.
    Takenaka T; Yano T; Morodomi Y; Ito K; Miura N; Kawano D; Shoji F; Baba S; Abe K; Honda H; Maehara Y
    Surg Today; 2012 Oct; 42(10):934-9. PubMed ID: 22864936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing diffusion-weighted imaging and positron emission tomography for pulmonary nodules measuring from 1 to 3 cm in size.
    Nomori H; Cong Y; Sugimura H; Kato Y
    Surg Today; 2015 Dec; 45(12):1535-41. PubMed ID: 25673032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma?
    Ito R; Iwano S; Kishimoto M; Ito S; Kato K; Naganawa S
    Ann Nucl Med; 2015 Dec; 29(10):897-905. PubMed ID: 26342592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer.
    Kanauchi N; Oizumi H; Honma T; Kato H; Endo M; Suzuki J; Fukaya K; Sadahiro M
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):706-10; discussion 710-1. PubMed ID: 19216085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness.
    Shibata H; Nomori H; Uno K; Iyama K; Tomiyoshi K; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
    Ann Nucl Med; 2009 Sep; 23(7):609-16. PubMed ID: 19562438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma.
    Nomori H; Watanabe K; Ohtsuka T; Naruke T; Suemasu K; Kobayashi T; Uno K
    J Thorac Cardiovasc Surg; 2004 Sep; 128(3):396-401. PubMed ID: 15354098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.